Efficacy and Safety Results from a Phase III, Randomised Controlled Trial Comparing the Safety and Efficacy of Briakinumab to Etanercept and Placebo in Patients with Moderate to Severe Chronic Plaque Psoriasis

Abstract

Background:  The TNF-α antagonist etanercept, and the IL-12/23p40 antagonist ustekinumab, have been shown to be effective psoriasis therapies. The IL-12/23 p40 antagonist briakinumab was shown to be effective psoriasis treatment in a Phase 2 study.


Objective:  To assess the efficacy, safety, and tolerability of briakinumab compared with etanercept and placebo in moderate to severe psoriasis patients.


Methods:  350 patients were enroled in this Phase III, 12-week study (M10-315, NCT00710580) and randomised in the following 2:2:1 ratio: 139 patients received 200 mg briakinumab at Weeks 0 and 4 followed by 100 mg briakinumab ...

Efficacy and Safety Results from a Phase III, Randomised Controlled Trial Comparing the Safety and Efficacy of Briakinumab to Etanercept and Placebo in Patients with Moderate to Severe Chronic Plaque Psoriasis is a post from: Skincare

Efficacy and Safety Results from a Phase III, Randomised Controlled Trial Comparing the Safety and Efficacy of Briakinumab to Etanercept and Placebo in Patients with Moderate to Severe Chronic Plaque Psoriasis via BuzzBlazer.com